Treatment Access
Find the information you need to initiate treatment with ZEMCELPRO®.
Patient Selection Considerations
Eligibility criteria
To be eligible for ZEMCELPRO®, the patient must meet all of the following criteria:
- Patient aged 18 years or older
- Patient with a malignant haematologic disease who is a candidate for allogeneic hematopoietic stem cell transplantation (HSCT) according to the transplant centre’s criteria
- Patient without a suitable available HSCT donor
Non-eligibility criteria
The patient is not eligible for ZEMCELPRO® if any of the following criteria apply:
- Hypersensitivity to the active substance or to any of the excipients
- Pregnancy
- Women of childbearing potential not using a highly effective contraceptive method
- Breastfeeding
- Contraindications to lymphodepleting chemotherapy
Refer to Product Information for complete CLINICAL PARTICULARS.
Centre Enrolment
ZEMCELPRO® is intended for administration in qualified transplant centres experienced in allogeneic hematopoietic stem cell transplantation and advanced cell therapies.
Cordex supports healthcare professionals throughout the treatment-access process, including patient registration, cord blood unit selection, logistic coordination, and clinical support.
Healthcare professionals interested in offering ZEMCELPRO® at their institution must complete the centre enrolment process by submitting the Transplant Centre (TC) Enrolment Form. This process can be initiated without a specific patient identified.
Following submission, a Cordex representative will contact the centre to coordinate the onboarding process and provide additional operational information.
Treatment Access Workflow
Access to ZEMCELPRO® involves a coordinated multi-step process including transplant centre onboarding, patient enrolment, cord blood unit selection, manufacturing, and product delivery.
Each ZEMCELPRO® product is manufactured from a patient-matched umbilical cord blood unit selected according to predefined medical and manufacturing criteria.
